`
`From: Beel, Bryan D. (Perkins Coie) <BBeel@perkinscoie.com>
`Sent: Monday, November 20, 2023 3:43 PM
`To: Megan Raymond <megan.raymond@groombridgewu.com>
`Cc: Novo-Semaglutide-IPR@groombridgewu.com; White, Brandon (Perkins Coie)
`<BMWhite@perkinscoie.com>; White-ptab@perkinscoie.com; Greb-ptab@perkinscoie.com;
`prochnow-ptab@perkinscoie.com; jones-ptab@perkinscoie.com; tietz-ptab@perkinscoie.com;
`lembo-ptab@perkinscoie.com; Semaglutide-Ozempic@perkinscoie.com; Beel, Bryan D. (Perkins
`Coie) <BBeel@perkinscoie.com>
`Subject: RE: IPR2023-00724
`
`Megan,
`
`Mylan does not agree to provide a Sotera stipulation. The trial date in the Ozempic district court
`litigation was ordered in June 2022 (22-cv-294, DI 22) and was explicitly disclosed and discussed in
`the Petition (Pet. at 65; Ex. 1082 (Scheduling Order)). Mylan addressed Fintiv in its Petition, yet the
`Patent Owner chose not to address that issue in its Preliminary Response. Moreover, the time to
`seek rehearing of the institution decision passed a month ago, and there has been no joinder of any
`proceeding with Mylan’s Petition, so there are no “new facts” to address. We can be available to
`meet and confer on November 22, if necessary. To the extent Novo intends to seek any relief from
`the Board, please provide your position before contacting the Board so we may add Mylan’s position.
`
`Best regards,
`Bryan
`
`Bryan Beel, Ph.D. | Perkins Coie LLP
`SENIOR COUNSEL
`1120 N.W. Couch Street Tenth Floor
`Portland, OR 97209-4128
`D. +1.503.727.2116
`F. +1.503.346.2116
`E. BBeel@perkinscoie.com
`
`
`
`
`
`From: Megan Raymond <megan.raymond@groombridgewu.com>
`Sent: Thursday, November 16, 2023 11:44 AM
`To: White, Brandon (WDC) <BMWhite@perkinscoie.com>; *White-ptab <White-
`ptab@perkinscoie.com>; *Greb-ptab <Greb-ptab@perkinscoie.com>; *prochnow-ptab <prochnow-
`ptab@perkinscoie.com>; *Jones-ptab <jones-ptab@perkinscoie.com>; *tietz-ptab <tietz-
`ptab@perkinscoie.com>; *lembo-ptab <lembo-ptab@perkinscoie.com>; *Semaglutide-Ozempic
`<Semaglutide-Ozempic@perkinscoie.com>
`Cc: Novo-Semaglutide-IPR@groombridgewu.com
`Subject: IPR2023-00724
`
`
`Novo Nordisk Exhibit 2540
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00001
`
`
`
`Counsel,
`
`
`
`Since the time of institution of the ‘462 IPR, two copycat petitions have been filed (which would
`remove the one-year statutory deadline for the issuance of the final written decision in Mylan’s IPR)
`and Mylan’s ‘462 trial date has been set for September 30, 2024. In view of these circumstances,
`and the Fintiv issues that are now implicated, we write to ask whether Mylan would agree to provide
`a Sotera stipulation rather than just the Sand Revolution stipulation it previously furnished. Please let
`us know by Monday, and whether you wish to have a telephonic meet and confer. If Mylan is not
`amenable to providing a Sotera stipulation, Petitioner will seek leave to file a request for rehearing
`now to brief Fintiv issues in view of the latest facts, and request that the IPR be uninstituted.
`
` Sincerely,
` Megan Raymond
`
`
`
`This message is intended only for the use of the addressee and may contain confidential and
`privileged information. Any review, use, or dissemination by anyone other than the addressee is s
`strictly prohibited. If you received this message in error, please notify us and delete all copies of this
` message.
`
`
`
`
`Novo Nordisk Exhibit 2540
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00002
`
`